IKNA vs. TRVI, DSGN, AVIR, AQST, RZLT, IMMP, CCCC, VYGR, YMAB, and MBIO
Should you be buying Ikena Oncology stock or one of its competitors? The main competitors of Ikena Oncology include Trevi Therapeutics (TRVI), Design Therapeutics (DSGN), Atea Pharmaceuticals (AVIR), Aquestive Therapeutics (AQST), Rezolute (RZLT), Immutep (IMMP), C4 Therapeutics (CCCC), Voyager Therapeutics (VYGR), Y-mAbs Therapeutics (YMAB), and Mustang Bio (MBIO). These companies are all part of the "pharmaceutical products" industry.
Ikena Oncology vs.
Trevi Therapeutics (NASDAQ:TRVI) and Ikena Oncology (NASDAQ:IKNA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends, profitability and community ranking.
95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 75.0% of Ikena Oncology shares are owned by institutional investors. 24.4% of Trevi Therapeutics shares are owned by insiders. Comparatively, 5.9% of Ikena Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Trevi Therapeutics has higher earnings, but lower revenue than Ikena Oncology. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Ikena Oncology, indicating that it is currently the more affordable of the two stocks.
Trevi Therapeutics has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, Ikena Oncology has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500.
Trevi Therapeutics received 65 more outperform votes than Ikena Oncology when rated by MarketBeat users. Likewise, 65.52% of users gave Trevi Therapeutics an outperform vote while only 58.82% of users gave Ikena Oncology an outperform vote.
Ikena Oncology's return on equity of -36.88% beat Trevi Therapeutics' return on equity.
Trevi Therapeutics presently has a consensus target price of $9.31, suggesting a potential upside of 148.00%. Ikena Oncology has a consensus target price of $3.00, suggesting a potential upside of 100.53%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Trevi Therapeutics is more favorable than Ikena Oncology.
In the previous week, Trevi Therapeutics had 4 more articles in the media than Ikena Oncology. MarketBeat recorded 4 mentions for Trevi Therapeutics and 0 mentions for Ikena Oncology. Trevi Therapeutics' average media sentiment score of 0.92 beat Ikena Oncology's score of 0.00 indicating that Trevi Therapeutics is being referred to more favorably in the media.
Summary
Trevi Therapeutics beats Ikena Oncology on 13 of the 17 factors compared between the two stocks.
Get Ikena Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for IKNA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ikena Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:IKNA) was last updated on 1/23/2025 by MarketBeat.com Staff
